CA
NZ
UK
AU
IND
US
Shattuck Labs (Nasdaq: STTK) has unveiled promising Phase 1 results for its Crohn's disease drug SL-325, a monoclonal antibody targeting the DR3 receptor to block TL1A-induced inflammation. The reported immunogenicity rate of 3.7% is a critical differentiator in a therapeutic landscape where conventional biologics …
In the ongoing battle against infectious diseases, the need for effective vaccines that can be deployed rapidly in outbreak zones has never been more pressing. Soligenix, a biopharmaceutical company focused on developing treatments for rare diseases and biodefense, is stepping into this critical arena …
Tango Therapeutics (Nasdaq: TNGX) has unveiled a remarkable breakthrough in the fight against pancreatic cancer, a disease notorious for its lethality and lack of effective treatmentOptions. The company reported an astonishing 92% objective response rate (ORR) for its combination therapy, which utilizes vopimetostat alongside …
Incyte Corporation has made a significantInvestmentin the burgeoning field of hematology by acquiring Vega Therapeutics for a total of $2 billion, which encompasses both upfront payments and future sales milestones. This acquisition is primarily driven by VGA039, a novel monoclonal antibody targeting Protein S, …
The acceptance of Alvotech's BLA for AVT16 marks a pivotal moment in the biosimilars landscape, particularly for the lucrative market dominated by Takeda's Entyvio. As healthcare costs continue to rise, the introduction of interchangeable biosimilars is increasingly compelling forStakeholders. With an estimated 30% reduction …
Eledon Pharmaceuticals has unveiled transformative data from its Phase 1b clinical trial, presenting a revolutionary advancement in the treatment of type 1 diabetes (T1D). The trial's results indicate that all participants receiving islet cell transplants infused with tegoprubart, an anti-CD40L antibody, achieved complete insulin …
Lyell Immunopharma (Nasdaq: LYEL) has achieved a remarkable milestone in CAR-T therapy through its novel prophylaxis protocol for LYL273, aimed at treating colorectal cancer. The addition of gastrointestinal (GI) prophylaxis significantly reduces the occurrence of Grade 2+ diarrhea and colitis from a concerning 55% …
Galmed Pharmaceuticals (Nasdaq: GLMD) recently made headlines with its acquisition of Colospan Ltd., a company specializing in medical devices designed to tackle anastomotic leaks, the most dreaded complication in colorectal surgery. These leaks, which can occur in 5-15% of surgeries, often necessitate additional interventions …
Eli Lilly and Company (NYSE: LLY) is the most valuable health-care company in the S&P 500, with a marketCapitalizationaround $1.01 trillion in mid-2026. Lilly has become one of the defining growth stories of the decade, driven by itsLeadershipin the booming market for GLP-1 medicines …
Johnson & Johnson (NYSE: JNJ) is one of the largest and most stable health-care companies in the S&P 500, with a marketCapitalizationaround $560 billion in mid-2026. With a history stretching back well over a century, J&J is a diversified health-care leader spanning pharmaceuticals and …
Please wait processing your request...